Abstract
Objective
The aim of this study is to explore if ABCG2 is related to the grade of glioma and resistance to chemotherapeutic drug for glioma.
Methods
The ABCG2 expression and distribution among glioma tissues of different grades and other samples were examined using tissue microarray technique. The enhancement of sensitivity of CD133+ glioma stem cells to chemotherapeutic agent, mitoxantone through addition of ABCG2 competitive inhibitor nicardipine was testified by MTT assay and FACS analysis.
Results
The positive immunostaining of ABCG2 was observed in less than 10% of low-grade gliomas (3/31 in grade I + II) and in more than 40% of high-grade gliomas (16/37 in grade III + IV), which was statistically different (χ 2 = 10.710, P = 0.0011). In samples consisting of glioma stem cells (CD133+), the positive-straining rate was 100% (4/4), while in CD133− fraction, no positive staining was observed. A simultaneous treatment of CD133+ tumor cells with concentration-dependent mitoxantone (10−5–1 µM) and 2.5/5.0 µM nicardipine resulted in synergistic cytotoxicity. The apoptotic rate of CD133+ cells treated with mitoxantone plus nicardipine was significantly higher than that treated with mitoxantone alone (58.54 ± 7.06% vs. 30.7 ± 3.79%, P < 0.01).
Conclusions
Our results showed that ABCG2 is also expressed in glioma stem cells and the expression level of ABCG2 is positively associated with the increasing pathological grade of glioma (poor cell differentiation). ABCG2 plays a key role in glioma cells resistance to mitoxantone, chemotherapeutic drug for glioma. Thus, inhibition of ABCG2 protein activity by nicardipine in glioma can sensitize it to mitoxantone, which may lead to better treatment strategies for cancers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allen JD, van Loevezijn A, Lakhi J (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417–425
Calli R, Rinda E, Orfanelli U (2004) Isolation and characterization of tumorigenic stem-like neural precursors from human glioblastoma. Cancer Res 64:7011–7021. doi:10.1158/0008-5472.CAN-04-1364
Chearwae W, Anuchapreeda S, Nandigama K (2004) Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol 68:2043–2052. doi:10.1016/j.bcp.2004.07.009
Chu L, Huang Q, Dong J, Wang AD, Lan Q (2006) Tumor stem cell drug resistance and treatment strategies. New Drugs Clin Mag (China) 25:868–872
Condo T, Setoguchi T, Taga T (2004) Persistence of a small subpopulation of cancer stem-like cells in the C6 glimo cell line. Proc Natl Acad Sci USA 101:781–786. doi:10.1073/pnas.0307618100
Doyle LA (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665–15670. doi:10.1073/pnas.95.26.15665
Goodell MA, Brose K, Paradis G (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. Exp Med 183:1797–1806. doi:10.1084/jem.183.4.1797
Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58. doi:10.1038/nrc706
Holm PS, Scanlon KJ, Dietel M (1994) Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85–181RDB) by introduction of a hammerhead ribozyme. Br J Cancer 70:239–243
Huang Q (2007) The status and future of research on Glioma stem cell. Chin Nerve J Med 6:865–868
Huang Q, Dong J, Zhu YD, Zhang QB, Lan Q (2006) Isolate and culture tumor stem cells from human glioma tissue. Tumor Mag (China) 28:331–333
Ji XY, Huang Q, Dong J (2006) Brain tumor stem cells in vitro differentiation of patterns, and signs and cell proliferation kinetics. Chin Med 86:1604–1609
Liu C, Qureshi IA, Ding X (1996) Modulation of multidrug resistance gene (mdr-1) with antisense oligodeoxynucleotides. Clin Sci 91:93–98
Mohan A, Kandalan M, Ramkumal HL (2006) Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma. Br J Ophthalmol 90:889–893. doi:10.1136/bjo.2005.089219
Shukla S, Robey RW, Bates SE (2006) The calcium channel blockers, 1, 4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 45:8940–8951. doi:10.1021/bi060552f
Singh SK, Clarke ID, Terasaki M (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828
Singh SK, Hawkins C, Clarke ID (2004) Identification of human brain tumors initiating cells. Nature 432:396–401. doi:10.1038/nature03128
Slater LM, Sweet P, Stupecky M, Gupta S (1986) Cyclosporin-A reverses vincristine and daunorubicin resistance in acute lymphoblastic leukemia in vitro. J Clin Invest 77:1405–1466. doi:10.1172/JCI112450
Wang JP, Huang Q, Zhang QB, Wang AD, Dong J (2005) Clone and identify human glioma stem cells from SHG44s. Tumor Clin (China) 32:604–606
Zhang QB, Huang Q, Lan Q (2005) The hot issue and progress of brain tumor stem cell research. Chin Med 85:1868–1870
Zhang QB, Ji XY, Huang Q, Zhu YD (2006) Differentiation profile of brain tumor stem cells: a comparative study with neural stem cells. Cell Res 16:909–915. doi:10.1038/sj.cr.7310104
Acknowledgments
This study was supported by Natural Science Foundation of Jiangsu province (BK2008173) and National Natural Science Foundation of China (No. 30672164; 30772241).
Author information
Authors and Affiliations
Corresponding author
Additional information
Y. Jin and Z. Q. Bin contributed equally to this paper.
Rights and permissions
About this article
Cite this article
Jin, Y., Bin, Z.Q., Qiang, H. et al. ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol 135, 1369–1376 (2009). https://doi.org/10.1007/s00432-009-0578-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-009-0578-4